**Supplementary file 3: Additional analyses according to assigned treatment group**

Title: Health-related quality of life in patients with recurrent *Clostridioides difficile*infections

Journal: Therapeutic Advances in Gastroenterology

Authors: Lianna H Hammeken, Simon M D Baunwall, Jens F Dahlerup, Christian L Hvas, Lars H Ehlers

Corresponding author: Lianna H Hammeken. Email: lhham@dcm.aau.dk

**Table 1.** Health-related quality of life measured by the EQ-5D-3L and EQ-VAS at baseline and at weeks 8 and 26 of follow-up.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **Baseline** | **Week 8** | **Week 26** | **Difference between baseline and week 8** | **Difference between baseline and week 26** |
| **EQ-5D-3L index: Base case (n=64)** |
| FMT, mean (SE) | 0.625 (0.049) | 0.821 (0.041) | 0.700 (0.065) | 0.196 (0.051) | 0.075 (0.063) |
| Fidaxomicin, mean (SE) | 0.726 (0.038) | 0.822 (0.039) | 0.811 (0.035) | 0.096 (0.036) | 0.084 (0.036) |
| Vancomycin, mean (SE) | 0.671 (0.061) | 0.789 (0.060) | 0.825 (0.058) | 0.118 (0.075) | 0.154 (0.068) |
| **EQ-VAS: Base case (n=64)** |
| FMT, mean (SE) | 53.8 (5.2) | 72.0 (3.3) | 65.8 (4.9) | 18.2 (4.6) | 12.0 (6.5) |
| Fidaxomicin, mean (SE) | 51.2 (3.5) | 68.5 (4.2) | 74.9 (3.4) | 17.3 (4.6) | 23.7 (4.6) |
| Vancomycin, mean (SE) | 50.9 (5.1) | 63.9 (7.0) | 70.5 (5.1) | 12.9 (8.4) | 19.6 (6.2) |

**Table 2.** Differencces in development in patients’ health-related quality of life measured by the EQ-5D-3L and EQ-VAS at baseline and at weeks 8 and 26 of follow-up.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Fidaxomicin vs FMT**  | **P-value** | **Vancomycin vs FMT** | **P-value** |
| **EQ-5D-3L index: Base case (n=64)** |
| Difference in increase in HRQoL between baseline and week 8 (unadjusted) | -0.100 (0.068) | 0.148 | -0.078 (0.079) | 0.333 |
| Difference in increase in HRQoL between baseline and week 8 (adjusted for baseline utility) | -0.035 (0.056) | 0.540 | -0.048 (0.066) | 0.467 |
| Difference in increase in HRQoL between baseline and week 26 (unadjusted) | 0.009 (0.074) | 0.905 | 0.079 (0.087) | 0.371 |
| Difference in increase in HRQoL between baseline and week 26 (adjusted for baseline utility) | 0.062 (0.067) | 0.361 | 0.103 (0.079) | 0.201 |
| **EQ-VAS: Base case (n=64)** |
| Difference in increase in HRQoL between baseline and week 8 (unadjusted) | -1.0 (7.2) | 0.894 | -5.3 (8.5) | 0.539 |
| Difference in increase in HRQoL between baseline and week 8 (adjusted for baseline utility) | -2.8 (5.7) | 0.620 | -7.4 (6.9) | 0.293 |
| Difference in increase in HRQoL between baseline and week 26 (unadjusted) | 11.6 (7.8) | 0.141 | 7.6 (8.9) | 0.399 |
| Difference in increase in HRQoL between baseline and week 26 (adjusted for baseline utility) | 9.5 (5.8) | 0.110 | 5.2 (6.9) | 0.453 |